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Factors that trigger human infection with animal influ-
enza virus progressing into a pandemic are poorly 
understood. Within a project developing an evidence-
based risk assessment framework for influenza viruses 
in animals, we conducted a review of the literature for 
evidence of human infection with animal influenza 
viruses by diagnostic methods used. The review cov-
ering Medline, Embase, SciSearch and CabAbstracts 
yielded 6,955 articles, of which we retained 89; for 
influenza A(H5N1) and A(H7N9), the official case 
counts of t       he World Health Organization were 
used. An additional 30 studies were included by scan-
ning the reference lists. Here, we present the findings 
for confirmed infections with virological evidence. We 
found reports of 1,419 naturally infected human cases, 
of which 648 were associated with avian influenza 
virus (AIV) A(H5N1), 375 with other AIV subtypes, and 
396 with swine influenza virus (SIV). Human cases 
naturally infected with AIV spanned haemaggluti-
nin subtypes H5, H6, H7, H9 and H10. SIV cases were 
associated with endemic SIV of H1 and H3 subtype 
descending from North American and Eurasian SIV lin-
eages and various reassortants thereof. Direct expo-
sure to birds or swine was the most likely source of 
infection for the cases with available information on 
exposure.
Introduction
Influenza virus type A, a member of the fam-
ily Orthomyxoviridae, is an enveloped virus with a 
negative-sense, single-stranded RNA genome organ-
ised in eight gene segments, which encode at least 
eleven proteins. Antigenic and genetic diversity of two 
surface glycoproteins, haemagglutinin (HA) and neu-
raminidase (NA), is used to classify type A influenza 
viruses into subtypes; 18 HA and 11 NA subtypes are 
known to date [1-5]. Water- and shorebirds were iden-
tified as reservoirs harbouring all subtypes, except 
A(H17N10) and A(H18N11) of which RNA was recently 
detected in bats from Guatemala and Peru, respectively 
[2,3]. Reservoir animals typically do not display symp-
toms. In contrast, the diversity of influenza viruses 
in mammalian hosts is limited to specific subtypes. 
Human-adapted seasonal influenza viruses since the 
beginning of the 20th century have had HA subtypes 
H1, H2 and H3, combined with NA subtypes N1 and N2. 
The segmented nature of the genome facilitates the 
exchange of genetic material if a host is co-infected 
with two genetically different type A influenza viruses. 
This reassortment process, also known as antigenic 
shift if it involves the gene segment encoding the HA, 
can result in the generation of viruses with surface 
antigens against which the human population may not 
have pre-existing, protective antibodies. Additional 
flexibility is conferred by the accumulation of muta-
tions during replication, potentially resulting in amino 
acid substitutions that can affect pre-existing immunity 
if the HA is involved (antigenic drift), host range, viru-
lence, and other factors [6]. If this results in sustained 
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human-to-human transmission of a virus against which 
a large proportion of the world’s human population is 
immunologically naïve a pandemic can develop result-
ing in a large number of human cases occurring simul-
taneously worldwide [7,8]. Such novel introductions 
of reassorted viruses were at the root of four influ-
enza pandemics in the last 100 years, and claimed 
the lives of millions of people, namely the ‘Spanish 
flu’ A(H1N1) in 1918, the ‘Asian flu’ A(H2N2) in 1957, 
the ‘Hong Kong flu’ A(H3N2) in 1968, and the recent 
pandemic caused by influenza A(H1N1)pdm09 in 2009 
[9,10]. Influenza A(H1N1)pdm09 has replaced previous 
human seasonal A(H1N1) viruses [11] and, together with 
A(H3N2) and influenza B viruses, has been causing 
seasonal influenza epidemics in humans since 2009. 
With the emergence of the influenza A(H3N2) pandemic 
in 1968, influenza A(H2N2) viruses ceased to circulate 
in humans, but H2 subtypes are still present in birds 
and were also recently isolated from diseased swine 
[12,13].
The factors that determine whether an animal influenza 
virus may acquire the ability to efficiently spread among 
humans are poorly understood [14]. Reassortment is 
not a necessary prerequisite for human infection, and 
there is clear documentation of direct transmission and 
human disease caused by animal influenza viruses, in 
particular avian (AIV) and swine (SIV) influenza viruses 
, such as AIV A(H5N1), A(H9N2) and various H7 sub-
types, as well as European avian-like SIV A(H1N1) [15-
22]. Early detection and in-depth investigation of such 
events may provide clues for (future) risk assessment 
of animal-to-human transmissions. 
This review was conducted under the framework of the 
FLURISK project funded by the European Food Safety 
Figure 1
Search strategy for the literature review on animal influenza A virus infections in humans
AV: avian; SW: swine; EQ: equine; H: human.
Selection step 1 extracted studies indicating information on human infection with animal influenza viruses in title and abstract. Selection 
step 2 excluded papers as specified in Inclusion and exclusion criteria. Seven articles described virological as well as serological evidence 
of infection. These references were counted once in the total count and listed twice in the row ’Articles according to type of evidence’. The 
virological evidence of human infection is presented in this paper. The indirect serological evidence will be described elsewhere. 
Complete search 
output:
Total after selection 
criterion 1:
Total after selection 
criterion 2:
Articles retrieved 
in addition to 
literature search:
19 AV-H
8 SW-H
3 EQ-H
TOTAL 
REFERENCES 
INCLUDED: 119 
Medline
4,905
185 AV-H
86 SW-H
35 AV-H
45 SW-H
1 EQ-H
Embase
631
21 AV-H
2 SW-H
0 AV-H
1 SW-H
SciSearch
553
29 AV-H
3 SW-H
3 AV-H
0 SW-H
CabAbstracts
866
23 AV-H
6 SW-H
2 AV-H
2 SW-H
Virological
evidence: 59
Serological 
evidence: 60
No serologic 
evidence found: 7
Articles according 
to type of 
evidence:
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 c
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 s
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at
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at
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 c
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: p
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 c
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 re
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t c
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 c
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 c
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os
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 c
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 p
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ltr
y 
an
d 
lo
w
 s
ea
so
na
l i
nf
lu
en
za
 a
ct
iv
it
y 
at
 
th
at
 ti
m
e.
d   
O
ne
 p
at
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at
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ra
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at
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 o
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f c
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 c
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 s
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at
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at
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 c
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: p
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 c
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t c
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 c
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 c
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at
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f e
xp
os
ur
e
Lo
ca
tio
n
Re
fe
re
nc
e
19
88
1/
1 
(fa
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 c
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l c
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; o
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 c
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w
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sp
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at
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ss
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 c
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l c
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tu
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 s
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ke
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eg
g 
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re
; 
M
DC
K 
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ll 
cu
ltu
re
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an
d 
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ss
ay
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se
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en
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ot
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en
ta
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nf
ec
tio
n 
of
 s
w
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e 
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ar
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en
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 p
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in
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19
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 p
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at
io
n 
an
d 
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in
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r-
ol
d 
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th
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an
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ng
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lth
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ta
tu
s 
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 p
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s 
un
kn
ow
n)
M
in
ne
so
ta
, U
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te
d 
St
at
es
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m
ur
a 
et
 a
l. 
19
98
 [3
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19
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H3
N2
n
M
ild
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I
M
DC
K 
ce
ll 
cu
ltu
re
; H
I  
an
d 
NI
 a
ss
ay
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RT
-P
CR
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eq
ue
nc
in
g
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on
th
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ld
 g
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th
er
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or
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 fa
m
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d 
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nt
 c
on
ta
ct
 w
ith
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ig
s)
Ho
ng
 K
on
go
 
Gr
eg
or
y 
et
 a
l. 
20
01
 [3
9]
20
02
1/
1
H1
N1
p
IL
I
M
DC
K 
ce
ll 
cu
ltu
re
; H
I a
ss
ay
 (a
ls
o 
se
ro
lo
gi
ca
lly
 c
on
fir
m
ed
 b
y 
HI
)
50
-y
ea
r-
ol
d 
fa
rm
er
 (p
os
si
bl
y 
fr
om
 p
ig
s 
sh
ow
in
g 
re
sp
ira
to
ry
 s
ym
pt
om
s)
Sw
itz
er
la
nd
Gr
eg
or
y 
et
 a
l. 
20
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 [2
1]
20
04
, 
20
05
1/
1
1/
1
H1
N2
q
H1
N1
q
M
ild
 IL
I
M
DC
K 
ce
ll 
cu
ltu
re
; H
A 
as
sa
y 
(tu
rk
ey
 
RB
C)
; H
I a
ss
ay
r ; 
ra
pi
d 
te
st
ss
; R
T-
PC
R;
 
se
qu
en
ci
ng
25
- a
nd
 4
-y
ea
r-
ol
d 
m
al
e;
 n
ei
th
er
 h
ad
 d
ire
ct
 
co
nt
ac
t t
o 
pi
gs
 (i
nc
id
en
ta
l c
on
ta
ct
 w
ith
 
ba
ck
ya
rd
 p
ig
s 
co
ul
d 
no
t b
e 
ex
cl
ud
ed
)
Ph
ili
pp
in
es
Th
ai
la
nd
Ko
m
ad
in
a 
et
 a
l. 
20
07
 [8
5]
W
he
re
 m
or
e 
th
an
 o
ne
 h
um
an
 c
as
e 
is
 s
ta
te
d,
 d
ia
gn
os
tic
 te
st
s 
w
er
e 
pe
rf
or
m
ed
 fo
r a
ll 
ca
se
s 
as
 s
ta
te
d 
in
 th
e 
M
et
ho
ds
 s
ec
tio
n,
 u
nl
es
s 
ot
he
rw
is
e 
sp
ec
ifi
ed
.
BS
L:
 b
io
sa
fe
ty
 le
ve
l; 
cl
: c
la
ss
ic
al
 s
w
in
e 
lin
ea
ge
; H
A:
 h
ae
m
ag
gl
ut
in
at
io
n;
 H
eL
a:
 H
en
rie
tt
e 
La
ck
s 
ce
rv
ic
al
 c
an
ce
r c
el
ls
; H
I: 
ha
em
ag
gl
ut
in
at
io
n 
in
hi
bi
tio
n;
 IL
I: 
In
flu
en
za
-li
ke
 il
ln
es
s;
 M
Ab
: m
on
oc
lo
na
l a
nt
ib
od
ie
s;
 
M
DC
K:
 M
ad
in
 D
ar
by
 c
an
in
e 
ki
dn
ey
; M
N:
 m
ic
ro
ne
ut
ra
lis
at
io
n;
 n
.a
.: 
no
t a
pp
lic
ab
le
; N
I: 
ne
ur
am
in
id
as
e 
in
hi
bi
tio
n;
 R
BC
: r
ed
 b
lo
od
 c
el
ls
; R
T-
PC
R:
 re
ve
rs
e 
tr
an
sc
rip
ta
se
 p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n;
 r
tR
T-
PC
R:
 
re
al
-t
im
e 
re
ve
rs
e 
tr
an
sc
rip
ta
se
 p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n;
 s
w
: s
w
in
e;
 S
w
L:
 s
w
in
e-
lik
e;
 tr
: t
rip
le
 re
as
so
rt
an
t;
 W
I-3
8:
 h
um
an
 e
m
br
yo
 lu
ng
 fi
br
ob
la
st
.
a  
In
 m
os
t c
as
es
 th
e 
nu
m
be
r t
es
te
d 
re
fle
ct
s 
on
ly
 th
e 
co
nf
irm
ed
 c
as
es
 re
po
rt
ed
 in
 th
e 
re
vi
ew
ed
 p
ap
er
 w
he
re
 th
e 
au
th
or
s 
di
d 
no
t r
ep
or
t o
n 
th
e 
tr
ue
 n
um
be
r o
f s
us
pe
ct
ed
 c
as
es
 te
st
ed
.
h  
Hi
gh
es
t h
om
ol
og
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w
ith
 E
ur
op
ea
n 
sw
in
e-
in
flu
en
za
 v
iru
se
s.
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Pa
tie
nt
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nd
 d
ev
el
op
ed
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I s
ym
pt
om
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e 
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y 
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 th
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tie
nt
 (v
iru
s 
is
ol
at
io
n 
no
t d
on
e)
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A/
M
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an
d/
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1.
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m
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an
 re
as
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an
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/N
et
he
rl
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ra
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r t
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 c
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w
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W
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nt
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 b
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 p
at
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 m
ot
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tr
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th
er
, b
ro
th
er
 a
nd
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s 
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ss
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Vi
ru
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 c
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se
ly
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la
te
d 
to
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iru
se
s 
ci
rc
ul
at
in
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in
 E
ur
op
ea
n 
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gs
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Ho
ng
 K
on
g 
Sp
ec
ia
l A
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in
is
tr
at
iv
e 
Re
gi
on
 (S
AR
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Ch
in
a.
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A/
Sw
itz
er
la
nd
/8
80
8/
02
 (E
ur
op
ea
n 
av
ia
n-
lik
e 
lin
ea
ge
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q  
Sw
in
e-
lik
e 
vi
ru
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s:
 H
A 
ge
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al
ly
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im
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r t
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e 
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ru
se
s 
ci
rc
ul
at
in
g 
in
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w
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a 
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 c
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ed
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th
 A
m
er
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 th
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90
s,
 w
he
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an
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in
te
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al
 g
en
es
 w
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e 
si
m
ila
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to
 E
ur
op
ea
n 
sw
in
e 
vi
ru
se
s.
r  
Bo
th
 is
ol
at
es
 te
st
ed
 n
eg
at
iv
e 
ag
ai
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t h
um
an
 s
tr
ai
ns
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s  
To
 d
et
er
m
in
e 
w
he
th
er
 is
ol
at
es
 b
el
on
g 
to
 in
flu
en
za
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 o
r B
.
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at
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 o
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, r
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 re
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 c
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m
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 m
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 b
ef
or
e 
ill
ne
ss
; a
ss
is
te
d 
in
 b
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 c
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l. 
20
07
 [9
6]
20
07
1/
1y
tr
H3
N2
w
Pa
ro
tit
is
, n
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at
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 b
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et
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09
 [9
5]
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z
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I
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at
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 s
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in
g
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 e
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l s
w
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 c
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O
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St
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es
Vi
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t e
t a
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09
 [8
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l. 
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/1
a)
 s
w
 tr
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N1
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H1
N2
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Ra
ng
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g 
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 m
ild
 
IL
I t
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eu
m
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Ra
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t o
f c
ar
e 
te
st
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=
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s 
cu
ltu
re
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=
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t R
T-
PC
R 
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=
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; H
I a
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ay
; c
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pl
et
e 
ge
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m
e 
py
ro
se
qu
en
ci
ng
Se
ve
n 
m
al
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 (a
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: 1
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m
on
th
s–
36
 y
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rs
)
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r f
em
al
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: 4
–4
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ye
ar
s)
; e
xp
os
ur
e 
ra
ng
in
g 
fr
om
 u
nk
no
w
n 
co
nt
ac
t, 
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os
e 
pr
ox
im
it
y 
an
d 
di
re
ct
 c
on
ta
ct
 w
ith
 s
w
in
e 
(s
om
e 
 p
ig
s 
w
er
e 
ill
)
W
is
co
ns
in
, 
M
is
so
ur
i, 
Io
w
a 
(n
=
3)
, O
hi
o 
(n
=2
), 
Ill
in
oi
s,
 M
ic
hi
ga
n,
 
M
in
ne
so
ta
 a
nd
 
Te
xa
s,
 U
ni
te
d 
St
at
e
Sh
in
de
 e
t a
l. 
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 [9
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W
he
re
 m
or
e 
th
an
 o
ne
 h
um
an
 c
as
e 
is
 s
ta
te
d,
 d
ia
gn
os
tic
 te
st
s 
w
er
e 
pe
rf
or
m
ed
 fo
r a
ll 
ca
se
s 
as
 s
ta
te
d 
in
 th
e 
M
et
ho
ds
 s
ec
tio
n,
 u
nl
es
s 
ot
he
rw
is
e 
sp
ec
ifi
ed
.
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L:
 b
io
sa
fe
ty
 le
ve
l; 
cl
: c
la
ss
ic
al
 s
w
in
e 
lin
ea
ge
; H
A:
 h
ae
m
ag
gl
ut
in
at
io
n;
 H
eL
a:
 H
en
rie
tt
e 
La
ck
s 
ce
rv
ic
al
 c
an
ce
r c
el
ls
; H
I: 
ha
em
ag
gl
ut
in
at
io
n 
in
hi
bi
tio
n;
 IL
I: 
In
flu
en
za
-li
ke
 il
ln
es
s;
 M
Ab
: m
on
oc
lo
na
l a
nt
ib
od
ie
s;
 
M
DC
K:
 M
ad
in
 D
ar
by
 c
an
in
e 
ki
dn
ey
; M
N:
 m
ic
ro
ne
ut
ra
lis
at
io
n;
 n
.a
.: 
no
t a
pp
lic
ab
le
; N
I: 
ne
ur
am
in
id
as
e 
in
hi
bi
tio
n;
 R
BC
: r
ed
 b
lo
od
 c
el
ls
; R
T-
PC
R:
 re
ve
rs
e 
tr
an
sc
rip
ta
se
 p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n;
 r
tR
T-
PC
R:
 
re
al
-t
im
e 
re
ve
rs
e 
tr
an
sc
rip
ta
se
 p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n;
 s
w
: s
w
in
e;
 S
w
L:
 s
w
in
e-
lik
e;
 tr
: t
rip
le
 re
as
so
rt
an
t;
 W
I-3
8:
 h
um
an
 e
m
br
yo
 lu
ng
 fi
br
ob
la
st
.
a  
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 m
os
t c
as
es
 th
e 
nu
m
be
r t
es
te
d 
re
fle
ct
s 
on
ly
 th
e 
co
nf
irm
ed
 c
as
es
 re
po
rt
ed
 in
 th
e 
re
vi
ew
ed
 p
ap
er
 w
he
re
 th
e 
au
th
or
s 
di
d 
no
t r
ep
or
t o
n 
th
e 
tr
ue
 n
um
be
r o
f s
us
pe
ct
ed
 c
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es
 te
st
ed
.
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 c
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an
 in
flu
en
za
 v
iru
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ay
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 m
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nt
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 b
ro
th
er
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 w
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ne
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tiv
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 a
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ay
.
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in
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th
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er
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an
 p
ig
s.
w
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e 
ge
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pe
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hu
m
an
/c
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ic
al
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w
in
e/
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re
as
so
rt
an
t t
ha
t e
m
er
ge
d 
in
 1
99
8 
in
 N
or
th
 A
m
er
ic
a.
x  
Fo
ur
 o
f s
ev
en
 h
ou
se
ho
ld
 m
em
be
rs
 o
f t
he
 p
at
ie
nt
 a
nd
 fo
ur
 o
f 4
6 
ot
he
r r
es
id
en
ts
 o
f t
he
 fa
rm
 s
ho
w
ed
 s
er
ol
og
ic
al
 e
vi
de
nc
e 
of
 in
fe
ct
io
n.
y  
Ho
us
eh
ol
d 
m
em
be
rs
 w
er
e 
on
ly
 s
er
ol
og
ic
al
ly
 s
cr
ee
ne
d.
z  
Vi
ru
s 
fr
om
 a
t l
ea
st
 tw
o 
in
di
vi
du
al
s 
w
as
 is
ol
at
ed
 a
nd
 s
eq
ue
nc
ed
 a
nd
 tu
rn
ed
 o
ut
 to
 b
e 
ne
ar
ly
 id
en
tic
al
 to
 th
e 
sw
H1
N1
 is
ol
at
ed
 fr
om
 th
e 
ill
 s
w
in
e;
 n
ot
 d
on
e 
fo
r a
ll 
hu
m
an
 c
as
es
.
aa
 H
A 
re
la
te
d 
to
 H
1γ
 c
lu
st
er
 (H
1N
2-
lik
e)
 o
f c
on
te
m
po
ra
ry
 H
1-
SI
V,
 N
A 
re
la
te
d 
to
 s
w
in
e 
N1
 p
hy
lo
ge
ne
tic
 c
lu
st
er
 a
nd
 in
te
rn
al
 g
en
es
 w
er
e 
fr
om
 tr
ip
le
-r
ea
ss
or
ta
nt
 S
IV
 li
ne
ag
e 
an
d 
gr
ou
p 
w
ith
 c
lu
st
er
 IV
 o
f A
(H
3N
2)
 
vi
ru
se
s.
bb
 H
1N
1:
 H
A,
 N
A,
 N
P,
 N
S,
 M
 (c
la
ss
ic
al
 s
w
in
e,
 N
or
th
-A
m
er
ic
an
 li
ne
ag
e)
, P
B2
, P
A 
(a
vi
an
, N
or
th
 A
m
er
ic
an
 li
ne
ag
e)
, P
B1
 (h
um
an
 s
ea
so
na
l H
3N
2)
.
cc
 H
1N
2:
 H
A 
(h
um
an
 s
ea
so
na
l H
1N
1)
, N
P,
 M
, N
S 
(c
la
ss
ic
al
 s
w
in
e,
 N
or
th
-A
m
er
ic
an
 li
ne
ag
e)
, P
B2
, P
A 
(a
vi
an
, N
or
th
-A
m
er
ic
an
 li
ne
ag
e)
, P
B1
, N
A 
(h
um
an
 s
ea
so
na
l H
3N
2)
.
9www.eurosurveillance.org
Ta
bl
e 
2d
V
iro
lo
gi
ca
l e
vi
de
nc
e 
of
 h
um
an
 in
fe
ct
io
n 
w
ith
 a
vi
an
 in
flu
en
za
 A
 v
ir
us
es
, e
xc
lu
di
ng
 h
ig
h 
pa
th
og
en
ic
ity
 A
(H
5N
1)
Ye
ar
(T
es
te
d)
a /
co
nf
irm
ed
 
ca
se
s
Su
bt
yp
e
Sy
m
pt
om
s
M
et
ho
d
Pa
tie
nt
 in
fo
rm
at
io
n 
an
d 
na
tu
re
 o
f e
xp
os
ur
e
Lo
ca
tio
n
Re
fe
re
nc
e
20
08
1/
1d
d
Sw
L 
tr
H1
N1
ee
IL
I, 
vo
m
iti
ng
, 
di
ar
rh
oe
a
Ra
pi
d 
te
st
; c
ul
tu
re
; r
RT
-P
CR
; 
se
qu
en
ci
ng
19
-y
ea
r-
ol
d 
m
al
e 
ex
po
se
d 
to
 h
ea
lth
y 
ap
pe
ar
in
g 
pi
gs
 (n
o 
ph
ys
ic
al
 c
on
ta
ct
)
So
ut
h 
Da
ko
ta
, U
ni
te
d 
St
at
es
Da
w
oo
d 
et
 a
l. 
20
11
 [9
0]
20
08
1/
1
sw
H1
N1
ff
IL
I
M
DC
K 
ce
ll 
cu
ltu
re
; 
im
m
un
of
lu
or
es
ce
nc
e 
us
in
g 
M
Ab
; 
PC
R;
 p
ar
tia
l s
eq
ue
nc
in
g
50
-y
ea
r-
ol
d-
fe
m
al
e 
w
ith
 d
ire
ct
 c
on
ta
ct
 to
 
as
ym
pt
om
at
ic
 p
ig
s
Sp
ai
n
Ad
ie
go
 S
an
ch
o 
et
 a
l. 
20
09
 [2
2]
20
09
1/
1g
g
sw
 tr
H3
N2
Fe
ve
r, 
co
ug
h,
 
so
re
 th
ro
at
Ra
pi
d 
te
st
; r
tR
T-
PC
R;
 s
eq
ue
nc
in
g
12
-y
ea
r-
ol
d 
bo
y 
(to
uc
he
d 
he
al
th
y 
ap
pe
ar
in
g 
sw
in
e 
at
 a
 c
ou
nt
y 
fa
ir,
 p
ig
s 
w
er
e 
se
ro
po
si
tiv
e)
Ka
ns
as
, U
ni
te
d 
St
at
es
Co
x 
et
 a
l. 
20
11
 [9
7]
20
09
3/
3h
h
sw
 tr
H1
N1
ii
IL
I
M
DC
K 
ce
ll 
cu
ltu
re
; r
tR
T-
PC
R;
 H
I 
as
sa
y 
(tu
rk
ey
 R
BC
)jj
, s
eq
ue
nc
in
g
Sw
in
e 
w
or
ke
rs
 (o
ne
 w
as
 im
m
un
iz
ed
 
in
 2
00
8,
 o
th
er
 tw
o 
ne
ve
r r
ec
ei
ve
d 
an
 
in
flu
en
za
 v
ac
ci
na
tio
n)
kk
Sa
sk
at
ch
ew
an
, C
an
ad
a
Ba
st
ie
n 
et
 a
l. 
20
10
 [9
1]
20
09
–1
1
3/
3
sw
H1
N1
ll
No
t s
pe
ci
fie
d
No
t s
pe
ci
fie
d
Th
re
e 
ad
ul
t, 
m
al
e 
sw
in
e 
w
or
ke
rs
 e
xp
os
ed
 
to
 il
l, 
in
flu
en
za
-c
on
fir
m
ed
 p
ig
s
Sw
itz
er
la
nd
Eu
ro
pe
an
 C
en
tr
e 
fo
r D
is
ea
se
 
Pr
ev
en
tio
n 
an
d 
Co
nt
ro
l 2
01
2 
[8
6]
Au
g-
 D
ec
 
20
11
20
12
20
13
12
/1
2m
m
30
9/
30
9
19
/1
9o
o
H3
N2
vn
n
IL
I, 
vo
m
iti
ng
, 
di
ar
rh
oe
a
Ra
pi
d 
te
st
s;
 r
tR
T-
PC
R;
 
se
qu
en
ci
ng
50
%
 e
xp
os
ed
 a
nd
 5
0%
 n
ot
 e
xp
os
ed
 to
 
sw
in
e;
 (1
1 
ch
ild
re
n,
 o
ne
 a
du
lt 
m
al
e)
; M
os
t 
at
te
nd
in
g 
ag
ric
ul
tu
ra
l f
ai
r
M
os
t a
tt
en
di
ng
 a
gr
ic
ul
tu
ra
l f
ai
r
Ha
w
ai
i, 
Ill
in
oi
s,
 In
di
an
a,
 
Io
w
a,
 M
ai
ne
, M
ar
yl
an
d,
 
M
ic
hi
ga
n,
 M
in
ne
so
ta
, 
O
hi
o,
 P
en
ns
yl
va
ni
a,
 
Ut
ah
, W
es
t V
irg
in
ia
, 
W
is
co
ns
in
, U
ni
te
d 
St
at
es
Un
ite
d 
St
at
es
 C
en
te
rs
 fo
r D
is
ea
se
 
Co
nt
ro
l a
nd
 P
re
ve
nt
io
n 
20
12
 
[9
9]
,2
01
3 
[2
5]
To
ta
l
45
5/
40
1
33
W
he
re
 m
or
e 
th
an
 o
ne
 h
um
an
 c
as
e 
is
 s
ta
te
d,
 d
ia
gn
os
tic
 te
st
s 
w
er
e 
pe
rf
or
m
ed
 fo
r a
ll 
ca
se
s 
as
 s
ta
te
d 
in
 th
e 
M
et
ho
ds
 s
ec
tio
n,
 u
nl
es
s 
ot
he
rw
is
e 
sp
ec
ifi
ed
.
BS
L:
 b
io
sa
fe
ty
 le
ve
l; 
cl
: c
la
ss
ic
al
 s
w
in
e 
lin
ea
ge
; H
A:
 h
ae
m
ag
gl
ut
in
at
io
n;
 H
eL
a:
 H
en
rie
tt
e 
La
ck
s 
ce
rv
ic
al
 c
an
ce
r c
el
ls
; H
I: 
ha
em
ag
gl
ut
in
at
io
n 
in
hi
bi
tio
n;
 IL
I: 
In
flu
en
za
-li
ke
 il
ln
es
s;
 M
Ab
: m
on
oc
lo
na
l a
nt
ib
od
ie
s;
 
M
DC
K:
 M
ad
in
 D
ar
by
 c
an
in
e 
ki
dn
ey
; M
N:
 m
ic
ro
ne
ut
ra
lis
at
io
n;
 n
.a
.: 
no
t a
pp
lic
ab
le
; N
I: 
ne
ur
am
in
id
as
e 
in
hi
bi
tio
n;
 R
BC
: r
ed
 b
lo
od
 c
el
ls
; R
T-
PC
R:
 re
ve
rs
e 
tr
an
sc
rip
ta
se
 p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n;
 r
tR
T-
PC
R:
 
re
al
-t
im
e 
re
ve
rs
e 
tr
an
sc
rip
ta
se
 p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n;
 s
w
: s
w
in
e;
 S
w
L:
 s
w
in
e-
lik
e;
 tr
: t
rip
le
 re
as
so
rt
an
t;
 W
I-3
8:
 h
um
an
 e
m
br
yo
 lu
ng
 fi
br
ob
la
st
.
a  
In
 m
os
t c
as
es
 th
e 
nu
m
be
r t
es
te
d 
re
fle
ct
s 
on
ly
 th
e 
co
nf
irm
ed
 c
as
es
 re
po
rt
ed
 in
 th
e 
re
vi
ew
ed
 p
ap
er
 w
he
re
 th
e 
au
th
or
s 
di
d 
no
t r
ep
or
t o
n 
th
e 
tr
ue
 n
um
be
r o
f s
us
pe
ct
ed
 c
as
es
 te
st
ed
.
dd
 
Co
nt
ac
ts
 o
f t
he
 p
at
ie
nt
 a
nd
 p
eo
pl
e 
ex
po
se
d 
to
 s
w
in
e 
du
rin
g 
th
e 
ev
en
t w
er
e 
se
ro
lo
gi
ca
lly
 s
cr
ee
ne
d.
ee
 D
is
tin
ct
 fr
om
 A
(H
1N
1)
pd
m
09
 a
nd
 s
im
ila
r t
o 
tr
ip
le
-r
ea
ss
or
ta
nt
 s
w
in
e 
vi
ru
se
s 
ci
rc
ul
at
in
g 
in
 th
e 
Un
ite
d 
St
at
es
 s
ho
rt
ly
 b
ef
or
e 
.
ff
 
Ph
yl
og
en
et
ic
al
ly
 c
lo
se
 to
 A
/S
w
itz
er
la
nd
/8
80
8/
02
 (E
ur
op
ea
n 
av
ia
n-
lik
e 
lin
ea
ge
) [
19
].
gg
 I
n 
ad
di
tio
n,
 2
7 
of
 3
4 
vi
si
to
rs
 o
f t
he
 c
ou
nt
y 
fa
ir 
pa
rt
ic
ip
at
ed
 in
 a
 s
ur
ve
y:
 n
on
e 
re
po
rt
ed
 IL
I.
hh
 N
o 
ho
us
eh
ol
d 
m
em
be
rs
 w
er
e 
ill
 a
t t
he
 ti
m
e.
ii  
Di
st
in
ct
 fr
om
 A
(H
1N
1)
pd
m
09
: N
S,
 N
P,
 M
, P
A,
 P
B1
 a
nd
 P
B2
 w
er
e 
si
m
ila
r t
o 
a 
No
rt
h-
Am
er
ic
an
 s
w
in
e 
tr
ip
le
 re
as
so
rt
an
t a
nd
 H
A 
an
d 
N
A 
w
er
e 
m
os
t s
im
ila
r t
o 
A/
Br
is
ba
ne
/5
9/
20
07
 (H
1N
1)
-li
ke
 v
iru
se
s.
jj  
Fo
r a
nt
ig
en
ic
 c
ha
ra
ct
er
is
at
io
n.
kk
 M
ild
 re
sp
ira
to
ry
 il
ln
es
s 
w
as
 p
re
se
nt
 in
 le
ss
 th
an
 1
%
 o
f t
he
 s
w
in
e 
he
rd
 th
e 
w
or
ke
rs
 w
er
e 
ex
po
se
d 
to
 (n
o 
co
nf
irm
at
io
n 
w
he
th
er
 it
 w
as
 d
ue
 to
 in
flu
en
za
 A
 in
fe
ct
io
n)
.
ll  
In
fe
ct
ed
 w
ith
 E
ur
op
ea
n 
SI
V 
si
m
ila
r t
o 
vi
ru
se
s 
id
en
tif
ie
d 
in
 il
l p
ig
s 
th
e 
w
or
ke
rs
 w
er
e 
ex
po
se
d 
to
.
m
m
 El
ev
en
 c
hi
ld
re
n 
(in
cl
ud
in
g 
tw
o 
ch
ild
re
n 
at
te
nd
in
g 
th
e 
sa
m
e 
da
yc
ar
e 
ce
nt
re
) a
nd
 o
ne
 a
du
lt 
m
al
e.
nn
 I
nf
lu
en
za
 A
 H
3N
2 
va
ria
nt
 (c
om
pr
is
es
 g
en
es
 fr
om
 a
vi
an
, s
w
in
e 
an
d 
hu
m
an
 o
rig
in
) w
ith
 M
 g
en
e 
de
ri
ve
d 
fr
om
 A
(H
1N
1)
pd
m
09
.
oo
 C
as
e 
co
un
t a
s 
av
ai
la
bl
e 
on
 3
1 
Ja
nu
ar
y 
20
14
.
10 www.eurosurveillance.org
Authority (EFSA). The main objective of FLURISK is 
the development of an evidence-based influenza risk 
assessment framework (IRAF) to assess the potential 
of animal influenza viruses to cross the species barrier 
and cause sustained infections in humans. The work 
presented here aims at describing available evidence 
for animal-to-human influenza virus transmissions. 
Methods
Search strategy
We performed a literature search using Medline, 
Embase, SciSearch and CabAbstracts. Search terms 
included ‘influenza’, ‘influenza virus’, ‘animals’, 
‘swine’, ‘birds’, ‘poultry’, ‘wild bird’, ‘water bird’, 
‘waterfowl’, ‘goose’, ‘duck’, ‘chicken’, ‘turkey’, ‘envi-
ronment’, ‘animal-to-human’, 
 ‘transmission-to-humans’, ‘interspecies transmission’, 
‘human’, ‘case’, ‘seroprevalence’, ‘serosurveillance’, 
‘prevalence’, ‘incidence’, ‘risk factor’, ‘exposure’ and 
various subtypes of influenza virus; the terms were 
used alone or in combinations using Boolean opera-
tors. Full search details are available from the corre-
sponding author on request. Only articles published 
in English were included and the search covered all 
years available in the respective databases, Medline 
from 1946, Embase from 1947, SciSearch from 1980, 
CabAbstracts from 1973, all up to February 2012. The 
search algorithm automatically discarded duplicates. 
Newly published evidence that came to our attention 
between February 2012 and January 2014 was also 
included. Case counts of avian influenza A(H7N9) and 
A(H5N1) cases were updated on 31 January 2014 based 
on the latest figures reported by the European Centre 
for Disease Prevention and Control (ECDC) [23] and by 
the World Health Organization (WHO) [24]. Case counts 
of human infections with swine influenza variant 
A(H3N2)v were retrieved on 31 January 2014 from the 
website of the United States (US) Centers for Disease 
Control and Prevention (CDC) as posted on 18 October 
2013 [25. Grey literature was searched in a non- sys-
tematic way. 
Inclusion and exclusion criteria
Included were papers indicating evidence of human 
infection with animal influenza viruses (selection cri-
terion 1, Figure 1). Two investigators first screened all 
papers by title and, when necessary, by abstract. All 
articles meeting this first criterion were reviewed for 
details of the methods used to diagnose the infec-
tion. Experimental and observational studies describ-
ing human infection with animal influenza viruses 
other than influenza A(H5N1) were included. Articles 
solely describing human infection with A(H5N1) were 
excluded, and for influenza A(H5N1) and A(H7N9), the 
official WHO and ECDC statistics from notifications 
under the International Health Regulations were used 
for completeness. Commentaries, reviews, articles 
dealing with influenza in animals only, studies solely 
assessing human-to-human transmission of an animal 
influenza virus (i.e. most of the literature on influenza 
A(H1N1)pdm09), and articles referring to study subjects 
described in prior original publications were excluded 
(selection criterion 2, Figure 1). Studies based on sero-
logical evidence only were excluded to ensure high 
specificity of the findings. Papers were screened for 
information on the time period when the study was 
conducted, total number of people sampled, patient 
information, nature of exposure (e.g. occupational, 
recreational), possible exposure to diseased animals, 
influenza virus subtypes included in testing, number of 
virologically confirmed cases, information on vaccina-
tion history if stated, methods used for confirmation, 
geographic region and study design. Available data 
were extracted and summarised in tables. Grey litera-
ture such as ProMED, and reference lists from articles 
were screened for possible additional relevant papers. 
Virus detection by culture or (real-time) reverse tran-
scription polymerase chain reaction (rtRT-PCR) and 
sequencing was considered to be definitive proof of 
infection, listed as virological evidence (Tables 1 and 
2). 
Search output and article selection
The initial search yielded 6,955 articles, with 4,905 
articles resulting from the Medline search, and the oth-
ers from additional searches (Figure 1). Search outputs 
from Embase, SciSearch and CabAbstracts yielded 631, 
553 and 866 references, respectively. After screening 
of titles, abstracts and application of the second selec-
tion criterion, a total of 89 publications were selected. 
The majority of these would also have been identified 
solely through the Medline search. 
 Thirty additional studies were retrieved through scan-
ning of reference lists of articles identified via the lit-
erature review, were retrieved from grey literature or 
came to our attention after February 2012. Of these 
119, 59 publications and reports described virologi-
cal evidence for infection of humans and met all other 
inclusion criteria; 60 papers provided some evidence 
for human infection, but only based on antibody test-
ing and will therefore be described elsewhere.. Seven 
publications containing both serological and viro-
logical evidence were counted once in the total refer-
ence count but were included twice in the subdivision 
according to type of evidence in Figure 1. 
Most studies discussed in a review of case reports 
of SIV infections in humans by Myers et al. [26] were 
also identified in our literature search. For complete-
ness of the human case count, virologically confirmed 
civilian (n=23) and military cases of Fort Dix (n=5), 
although discussed in detail in the review by Myers et 
al. [26], were also included in the current review [21,27-
42] (Table 2). For two virus-confirmed cases from the 
review by Myers et al. [26], the reference could not be 
retrieved or did not provide full confirmation; these 
cases were therefore excluded from our listing in Table 
2 [43,44]. 
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Results
The evidence for virologically confirmed infections of 
humans with avian or SIV is listed in Tables 1, 2 and 
3. The exposure status of infected patients is summa-
rised in Table 4. A total of 386 cases of human infec-
tion with non-A(H5N1) AIV were described, of which 375 
were caused by natural infection and 11 were infected 
experimentally (Table1). 
Regarding human infections with SIV, a total of 401 
naturally (n=396) and experimentally (n=5) infected 
cases were detected in the published and grey lit-
erature in English. This included, three virologically 
confirmed SIV A(H1N1) cases originally published in 
Russian by Chuvakova et al. [27] because they were 
listed in the review by Myers et al. [26]. The major-
ity of cases (n=340) were naturally infected by a SIV 
variant A(H3N2)v [25]. Recognised in US swine in 2010, 
this variant combines seven genes from the contem-
porary North-American A(H3N2) SIV lineage and has 
acquired the M gene of the A(H1N1)pdm09 virus [25]. 
The remaining 56 naturally infected, virologically con-
firmed human cases were caused by different circulat-
ing SIV or SIV reassortants (Table 2). Five persons were 
experimentally infected with SIV [45]. The majority of 
AIV- and SIV-infected patients had been exposed to 
animals (Table 4).
Human infections with avian influenza viruses
Infections with highly pathogenic avian influenza virus 
A(H5N1)
To date, highly pathogenic avian influenza (HPAI) 
A(H5N1) viruses are the most frequently diagnosed 
zoonotic influenza virus infections related to avian 
exposure [46], although this picture may change in the 
near future given the recent upsurge in low pathogenic 
avian influenza (LPAI) A(H7N9) cases. The HPAI A(H5N1) 
viruses first attracted major attention in the scientific 
community in 1996, when a large number of domestic 
waterfowl died in the course of an A(H5N1) outbreak in 
Guangdong province in southern China. In 1997, HPAI 
A(H5N1) resurfaced in Hong Kong SAR, China (in the fol-
lowing referred to as Hong Kong); it caused a massive 
die-off in poultry and crossed the species barrier for 
the first time, infecting 18 humans, of whom six died 
[47,48]. From mid-2003 to March 2004, HPAI A(H5N1) 
spread to seven south-east Asian countries with out-
breaks in poultry and waterfowl, and the first con-
firmed human cases, were reported in Thailand and 
Vietnam in 2004 [49]. In 2005, HPAI A(H5N1) accounted 
Table 3
Humans naturally infected with avian influenza virus subtypes other than A(H5N1) and swine influenza virus subtypes, 
1959–2014 (n=771)
Source
virus Number of human cases infected with
Avian
Subtype
LP
H6N1 H7N2
HP 
H7N3
LP
H7N3
HP 
H7N7
LP 
H7N7
LP
H7N9a H9N2 H10N7 H10N8 Total
1 4 3 2 89 4 251 15 4 2 375
Swine
Subtype
H1N1 H1N2 H3N2 H3N2vb Total
47 2 7 340 396
HP: highly pathogenic; LP: low pathogenic.
a as of 27 January 2014 [23].
b as of 18 October 2013 [25].
Table 4
Exposure status of patients infected with avian influenza virus, excluding 251 A(H7N9) and including 11 experimentally 
infected cases, and with swine influenza virus, 1959–2014 (n=536)
Source Number of cases
Exposed Not exposed Exposure status unknown
Likely exposed 
(H3N2v) Other
a Total
Avian 114 3 5 n.a. 13 135
Swine 45 20 2 328 6 401
n.a.: not applicable.
a Experimental (avian n=11, swine n=5) or laboratory exposure (avian n=2), or human-to-human transmission (swine n=1).
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for the death of a large number of migratory waterfowl 
at Qinghai lake, China. Shortly after this event, the 
virus rapidly spread to other Asian countries, Africa, 
Europe, the Middle East, Mongolia and Russia [50]. 
Over time, the viruses evolved into multiple lineages, 
some of which persisted and have become endemic 
in China, Bangladesh, Egypt, India, Indonesia and 
Vietnam [51].
As of 10 December 2013, the WHO has listed 648 HPAI 
A(H5N1) infected cases from 15 countries, confirmed 
according to WHO criteria and covering a time span of 
10 years [24]. In total, 59% of the reported cases died 
[24]. Indonesia, Egypt and Vietnam reported 195, 173 
and 125 cases, respectively, accounting for about 75% 
of the total influenza A(H5N1) human case count. These 
three countries also reported the majority of fatalities 
[24].
Infections with H7 subtype avian influenza viruses
In total, we identified 353 human cases with virologi-
cally confirmed H7 infection (Table 1). The majority of 
these cases (n=251) were reported in China, followed 
by 95 cases in Europe, six in North America and one 
in Australia [17,18,23,52–59]. In China, all cases were 
caused by the recently emerged subtype A(H7N9) [23]. 
Of the remaining 102 cases, 93 cases had influenza 
A(H7N7), five had influenza A(H7N3) and four influ-
enza A(H7N2) (Table 3). The first two human cases 
infected with influenza A(H7N7) were reported in 1959 
and 1977. One of these patients had keratoconjunctivi-
tis, thought to be caused by the AIV infection [52,53]. 
This predilection for the ocular mucosa was confirmed 
when a person involved in an experimental infection of 
a seal with an avian-like influenza A(H7N7) developed 
conjunctivitis, and virus was cultured from a conjuncti-
val swab [54,60]. In the United Kingdom (UK) in 1996, 
LPAI A(H7N7) virus infection was associated with mild 
conjunctivitis in a woman who cleaned a duck house 
and mentioned getting a piece of straw in her eye [55].
Among European cases, 89 humans were infected in 
the course of a large outbreak with HPAI A(H7N7) in 
poultry in the Netherlands in 2003 [17]. In contrast to 
the severe consequences in poultry, only mild symp-
toms were seen in 88 of the infected people. There 
was one exception. a veterinarian who died of acute 
respiratory distress syndrome and multiple organ fail-
ure. This person had contracted a virus with several 
mutations, including a known virulence marker in PB2 
[56]. Most of these mutations had accumulated dur-
ing circulation of the virus in poultry, showing that 
the public health risk may change over the course of 
an outbreak [61]. In February 2004, a mixed LPAI and 
HPAI A(H7N3) virus outbreak was reported in poultry in 
British Columbia, Canada [18]. Enhanced surveillance 
for influenza-like illness (ILI) and conjunctivitis in the 
course of this outbreak led to the identification of two 
poultry workers showing symptoms of unilateral con-
junctivitis. Neither had used the recommended gog-
gles or taken prophylactic oseltamivir. Interestingly, 
both virus types led to human infection: the isolate 
cultured from the first worker had the LPAI phenotype, 
whereas the strain retrieved from the second worker 
was classified as HPAI [19,62,63]. In 2006 and 2012, 
LPAI A(H7N3) was associated with one patient in the 
UK and HPAI A(H7N3) with two patients in Mexico. In 
both instances, exposure to infected poultry was docu-
mented and all patients presented with conjunctivitis 
[57,59]. Finally, LPAI A(H7N2) was reported as the infec-
tious agent causing mild influenza-like symptoms and 
conjunctivitis in four cases in the UK in 2007 [58].
The assumption that LPAI influenza viruses were mostly 
associated with mild disease was challenged with the 
emergence of influenza A(H7N9) viruses in March 2013, 
when China notified the WHO of three cases infected 
with LPAI A(H7N9) who were severely ill and eventu-
ally died [64]. During the first wave of infections from 
February to May 2013, 133 human cases were reported 
and an additional two cases in July and August [23]. 
Phylogenetic studies concluded that all genes of this 
newly detected virus were of avian origin [64]. In 
October 2013, the second wave started and was still 
ongoing at the time of writing (31 January 2014) [23]. 
Between February 2012 and 27 January 2014, a total of 
251 influenza A(H7N9) cases were reported, 56 of whom 
died [23]. Infections occurred in Anhui (n=4), Beijing 
(n=3), Fujian (n=15), Guangdong (n=32), Guizhou (n=1), 
Hebei (n=1), Henan (n=4), Hong Kong (n=3), Hunan 
(n=4), Jiangsu (n=31), Jiangxi (n=5), Shandong (n=2), 
Shanghai (n=42) and Zheijang (n=102). Two cases 
were imported from mainland China into Taiwan [23]. 
In response to these events, China culled thousands of 
birds and closed several poultry markets [65], although 
only 39 of 48,000 samples representing 1,000 poultry 
markets tested positive. Most human cases had a his-
tory of exposure to birds or live bird markets [23]. As of 
31 January 2014, no conclusive evidence of human-to-
human transmission has been reported and the ecol-
ogy of the viruses remains to be resolved. 
Infections with H9 subtype avian influenza viruses
In total, we detected 15 human cases infected with AIV 
A(H9N2) (Table 1, Table 3). Since the mid-1990s, influ-
enza viruses of the H9 subtype have established sta-
ble lineages in poultry in Asia and have occasionally 
infected humans and swine (Table 1) [16,66-69]. As of 
31 January 2014, human A(H9N2) cases have only been 
detected in Asia, particularly in China. Six cases were 
identified via the literature search [16,66-68]. Of those, 
three reported poultry exposure and all presented with 
mild ILI (Table 1). Reviews conducted by Peiris [46] and 
Cheng et al. [68] identified six additional human infec-
tions in China reported in the Chinese literature [70,71]. 
Three additional cases from Bangladesh, Hunan and 
Shenzhen, two with and one without poultry expo-
sure, complete the total count of fifteen human cases 
caused by AIV A(H9N2) [69,72,73] (Table 3). Infections 
with AIV A(H9N2) viruses gained public health inter-
est when researchers found that strains circulating 
in Asian poultry had a receptor specificity similar to 
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human influenza A viruses, which is considered one of 
the essential features of a human-to-human transmis-
sible virus [74]. So far, however, no sustained human-
to-human transmission of A(H9N2) influenza viruses 
has been reported. 
Infections with other avian influenza virus subtypes
Experimental inoculation of human volunteers with 
influenza strains A(H4N8), A(H6N1) or A(H10N7) resulted 
in mild clinical symptoms and virus shedding in eleven 
volunteers [75]. In 2004, the National Influenza Center 
in Egypt and the WHO Influenza Collaborating Centre in 
the UK announced the isolation of influenza A(H10N7) 
virus from two children presenting with fever and 
cough in Egypt [76]. In Australia, virus of the same sub-
type could be detected by PCR in two abattoir workers 
with conjunctivitis who were exposed to infected poul-
try [20] (Table 3). In December 2013 and January 2014, 
human infection with A(H10N8) virus was reported for 
the first time in Jiangxi province, China [77,78]. Both 
patients were female and had visited a poultry and 
an agricultural market, respectively, before onset of 
illness. One of them was immunocompromised and 
had died whereas the other case was still in critical 
condition as of 31 January 2014. In 2013, CDC Taiwan 
reported a human case of AIV A(H6N1) infection caus-
ing mild pneumonia, although an avian source could 
not be identified [79,80] (Table 3).
Human infection with swine influenza viruses
An overview of all studies describing virologically con-
firmed human SIV cases is given in Table 2. In total, 
we identified 396 SIV-confirmed patients who were 
naturally infected (401 including experimental infec-
tions) (Table 2). Beare et al. [45] successfully recovered 
SIV from five of 20 human volunteers after experimen-
tal infection: of seven volunteers infected with SIV 
A(H3N2) related to A/Hong Kong/1/68, three tested 
virus-positive), and of 13 infected with a classical swine 
A(H1N1) virus strain, two tested positive. Of the natu-
rally infected cases, 47 were infected with SIV A(H1N1), 
two with SIV A(H1N2), seven with SIV A(H3N2) and 340 
with SIV A(H3N2)v (Table 2, Figure 2). The majority 
of these cases were reported in North America, 11 in 
Europe and six in Asia. One of the six Asian cases was 
infected with SIV A(H3N2) from the European lineage 
(Figure 2) [39]. SIV epidemiology differs between conti-
nents and was extensively reviewed for North America, 
Europe and Asia [81-84]. In addition to the studies dis-
cussed in the review by Myers et al. [26] we identified 
fourteen studies and reports describing a further 28 
human SIV cases; 368 when taking into account 340 
cases with SIV A(H3N2)v infection. Details on these 
studies are described in more detail in the following 
sections grouped by continent.
Infections with swine influenza A H1 subtype viruses
Asia: A 25 year-old male from the Philippines and a 
four year-old male from Thailand were infected with 
swine-like A(H1N2) and A(H1N1), respectively [85]. The 
isolated viruses carried HA genes most closely related 
to classical swine viruses circulating in Asia and North 
America. NA genes were most similar to circulating 
European SIV. Both cases showed mild ILI and neither 
of them had direct contact with swine, although occa-
sional contact with backyard swine could not be ruled 
out.
Europe: In Spain, a 50 year-old woman developed ILI 
after having been closely exposed to swine on a family 
farm [22]. No symptoms in swine were observed and 
sequencing of the isolate revealed that it was closely 
related to avian-like SIV A(H1N1) circulating in swine 
in western Europe. Three cases from Switzerland were 
detected who had worked with influenza-confirmed 
swine [86].
North America: For the US, 19 confirmed cases of SIV 
A(H1N1) infection were described in the published lit-
erature. This number could possibly be higher because 
Vincent et al. [87] reported on 26 human cases pre-
senting with ILI after exposure to ill swine on a county 
fair in Ohio. The authors described that isolation and 
sequencing was performed for at least two of the 
human cases. Since the exact number of virologically 
confirmed cases was not given, we only added the two 
confirmed patients to the overall SIV A(H1N1) count 
(Table 3). Sequences from swine and human isolates 
from this outbreak were identical and were similar to 
triple–reassortant (tr) viruses currently circulating in 
swine herds in the US [87,88]. Another triple–reassor-
tant A(H1N1) SIV was detected in a 17 year-old male from 
Wisconsin who assisted in butchering healthy appear-
ing swine [89]. The patient presented with acute, mild 
respiratory illness without fever. Similarly, Dawood et 
al. [90] reported infection with trSIV A(H1N1) in a 19 
year-old asthmatic male who visited a swine show in 
South Dakota. Symptoms included fever, ILI, vomiting 
and diarrhoea. No respiratory illness was observed in 
swine at this event. A trSIV A(H1N1) was also detected in 
three infected swine workers in Sasketchewan, Canada 
[91]. Household members did not report any signs of 
disease. Mild respiratory illness was reported in less 
than 1% of the swine; however, no confirmatory test 
had been conducted in ill swine. Unlike trSIV identified 
earlier in North America, this isolate contained an HA 
and a NA belonging to the A/Brisbane/58/2007 A(H1N1) 
lineage, whereas the remaining genes were derived 
from trSIV A(H3N2) viruses circulating in North America 
since 1998. Gray et al. [92] found another trSIV A(H1N1) 
in the course of a prospective survey, which was iso-
lated from an ill swine farmer exposed to swine show-
ing respiratory symptoms. Routine national influenza 
surveillance reported another 10 human cases infected 
with trSIV A(H1N1), distinct from A(H1N1)pdm09, and 
one case caused by trSIV A(H1N2). The majority of 
those twelve patients stated exposure to swine prior to 
disease onset and all made a full recovery [93].
The CDC reported additional human infections with 
SIV-variant viruses of subtype A(H1N1)v and A(H1N2)v 
identified in the US since 2005 [94]. These figures have 
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Figure 2
Timeline of emergence of swine influenza virus lineages circulating in Europe and North America indicating natural human 
infections from swine 
HA: haemagglutinin; NA: neuraminidase; SIV: swine influenza virus; v: variant; hu: human.
Years on main arrow denote human influenza pandemics: A(H1N1) in 1918, A(H2N2) in 1957, A(H3N2) in 1968 and A(H1N1)pdm09 in 2009. 
Pictograms denote the origin of viral genes. Items in grey font indicate that the virus did not establish itself in the swine population and 
therefore did not circulate any further. Boxed items indicate infection in humans. Double-ended arrows indicate that four viruses were 
introduced in 1998 in the swine population.
Superscript letters refer to the genome segment constellation:
a  Classical SIV A(H1N1) constitutes a reassortant between human A/BM/1918 and unknown virus.
b  Recent phylogenetic evidence suggests that classical SIVA(H1N1) may have been present in Europe already in the 1930s and not around 
1950 as previously assumed [122].
c  Classical SIV A(H1N1) was re-introduced into Europe via Italy in 1976 and circulated in European countries until it was replaced by avian-like 
SIV(H1N1) in 1979 (was not replaced in England) [122].
d  HA and NA from human HongKong/68-like virus, remaining genes from European avian-like swine A(H1N1).
e  HA from human A(H1N1) (England/80-like), NA from European reassortant swine A(H3N2), remaining genes from European avian-like swine 
A(H1N1).
f  HA, NA of human A(H3N2) origin, remaining genes from classical swine A(H1N1) and avian influenza origin.
g  HA, NA from classical SIV A(H1N1), remaining genes from triple-reassortant or swine A(H1N2).
h  HA, NA from seasonal human influenza viruses, remaining genes from triple-reassortant swine A(H3N2).
i  A(H3N2)variant: M gene from A(H1N1)pdm09, remaining genes from triple-reassortant swine A(H3N2), N2 antigenically different from triple-
reassortant A(H3N2) from 1998.
j  Including five virus-confirmed human cases reported from Fort Dix outbreak among soldiers in New Jersey, United States in 1976 [28].
k  Nine human cases could not be assigned: Six of them were infected with reassortants that did not group with current SIV lineages. Two 
of the six cases were from the Philippines and Thailand, infected with A(H1N1) and A(H1N2) bearing HA from the North American lineage 
from the 1990s and NA from European swine influenza lineages [85]. Three of the six cases were from Canada, infected with an A(H1N1) 
reassortant with HA and NA genes resembling those of A/Brisbane/59/2007(H1N1)-like viruses and internal genes (NS, NP, M, PA, PB1, 
and PB2) descending from a contemporary North American SIV A(H3N2) triple reassortant [91]. The last of the six cases was infected with 
triple-reassortant A(H1N1) with HA, PA, PB1, PB2, NP, M, NS from North American triple-reassortant SIV A(H1N1) lineage and NA from North 
American, classical swine A(H1N1) [92,123]. The remaining three cases infected with SIV A(H1N1) were described in Russian by Chuvakova et 
al. [27] for which no further isolate characterisation was given in the abstract of the paper.
North 
America
19571918 1968 2009
1918
Classical A(H1N1)a 1998Triple-reassortant A(H3N2)f
16j
Europe
1979
European avian-like
A(H1N1)
1984
Reassortant A(H3N2)d
1994
Reassortant A(H1N2)e
1998
Reassortant A(H1N1)g
1998
Double-reassortant A(H3N2)
1998
Reassortant A(H1N2)
2003-05
Reassortant hu A(H1N1)h
Reassortant hu A(H1N2)h
4
14
1
9
3
340
2009
A(H1N1)pdm09
2009
A(H1N1)pdm09
2010
Reassortant A(H3N2)vi
9k
Total: 396 cases
Cumulative number of 
virologically confirmed, 
naturally infected 
human cases
2000
Reassortant A(H1N2)
+ ?
1970s
Human  A(H3N2)
1930
Classical A(H1N1)a,b
+ ?
1976
Classical A(H1N1)a,c
+ ?
15www.eurosurveillance.org
not been included in this review due to missing case 
history and in order to avoid double counting of cases 
described in the published literature.
Human infections with swine influenza A H3 subtype 
viruses
North America: In our search we detected two cases 
of trSIV A(H3N2) from Canada [95,96] and one from 
Kansas, US [97] infected before 2011. In Canada, a six 
year-old boy who lived on a swine farm presented with 
parotitis, nasal congestion, cough and pharyngitis, but 
had no fever. The swine appeared clinically healthy 
[95]. No swine exposure was reported in the second 
Canadian patient, a seven month-old child, who lived 
on a community farm and showed ILI symptoms [96]. 
Similarly, the third case from Kansas presented with 
ILI and is likely to have contracted trSIV A(H3N2) from 
swine he was exposed to at a county fair [97]. It is 
assumed that swine harboured the virus; PCR results 
performed on swine samples were negative but sera 
showed raised titres against SIV A(H3N2) indicating 
prior infection. 
Between July and August 2011, a SIV variant, which 
accounted for the majority of reported human SIV 
A(H3N2) cases, appeared in the US, possibly reflect-
ing enhanced surveillance activities in the country. 
This SIV A(H3N2) variant, A(H3N2)v, was first found 
in two children presenting with fever and respiratory 
signs [98,99]. Sequencing showed that this variant 
contained seven genes derived from the contemporary 
trSIV A(H3N2), circulating in the US swine population 
since 1998, as well as the M,gene from the A(H1N1)
pdm09 virus. Since its first occurrence in 2011, A(H3N2)
v has been detected in 340 humans according to data 
as of 18 October  2013 [25]. Since July 2012, 17 patients 
have been hospitalised and one patient has died due 
to SIV A(H3N2)v infection. Most cases have reported 
prolonged exposure to swine before getting ill.
Human infections following exposure to other animals 
We have identified three studies describing human 
susceptibility to equine influenza virus, demonstrated 
by experimental infection with equine subtype A(H3N8) 
[100-102]. The literature search did not reveal evidence 
of humans naturally infected with equine influenza 
virus.
Discussion
Here we present a review of the literature for stud-
ies presenting any evidence for human infection with 
animal influenza viruses. Virological techniques, e.g. 
virus culture, PCR and sequencing provide more solid 
evidence of infection, whereas serological methods 
can help reaching a diagnosis after the virus has been 
cleared from the body. Virus isolation is still the gold 
standard in detecting AIV infection. Human cases with 
virological evidence identified by PCR only should be 
interpreted with caution as detection of viral RNA with-
out additional serological evidence (seroconversion, 
more than fourfold rise in the titre of paired samples) 
does not necessary imply infection, although current 
diagnostic methods heavily rely on case identification 
by PCR [103,104]. Serological results can be misleading 
because of the existence of cross–reactive antibodies 
and thus provide less solid evidence than direct detec-
tion of the infecting virus itself [105]. Therefore, we lim-
ited the current paper to studies providing virological 
evidence only. 
Most evidence of human infection with AIV is associ-
ated with subtypes H5 and H7. Both subtypes can be 
linked to devastating outbreaks in poultry with high 
mortality, if transition from a low to a highly patho-
genic state occurs [106]. Pathogenicity shown in poul-
try clearly does not reflect disease severity in humans: 
before the emergence in LPAI A(H7N9) as a cause of 
severe human illness, LPAI and HPAI viruses of sub-
type H7 had in the majority of cases been associated 
with mild eye infections or ILI [107]. The LPAI A(H7N9) 
infections diagnosed to date, however, have been unu-
sually severe [23,64]. In addition to the severity of ill-
ness associated with these and also A(H5N1) viruses, 
the widespread circulation of different lineages, made 
possible by mutations and reassortments, justifies 
enhanced surveillance activities, given that few genetic 
changes may lead to a human-to-human transmissible 
virus [108,109]. 
Nevertheless, the evidence from experimental infec-
tions and anecdotal natural infections shows that other 
AIV may infect humans as well. There is insufficient 
systematic surveillance data to address the question 
whether the identified human cases reflect the level 
of virus circulation among wild or domestic birds, or 
whether certain subtypes infect humans preferentially. 
Regarding SIV, there is ample evidence of human infec-
tion with A(H3N2), A(H1N1) and A(H1N2) subtypes, as 
well as reassortants derived from these endemic SIV 
lineages. Nevertheless, one has to be aware that the 
true number of human SIV cases is probably higher 
than reported since clinical symptoms of SIV are indis-
tinguishable from seasonal influenza [86]. Whereas 
recent human cases in Europe were detected almost 
accidentally, the larger number of cases reported in the 
US since 2005, especially for influenza A(H3N2)v since 
2011, may be the result of increased surveillance activi-
ties [86,110]. Swine were assumed to play an important 
role as intermediate hosts or ‘mixing vessels’ for strains 
of human, avian and swine origin, because they pos-
sess avian and human influenza-specific receptors in 
the tracheal epithelium [111]. However, recent research 
showed that the distribution of sialic acid receptors 
in the porcine respiratory tract is similar to that in 
humans, leading to the conclusion that humans are 
equally likely to constitute ‘mixing vessels’ [112,113]. 
The fact that influenza viruses can circulate unnoticed 
in swine populations [114] warrants close surveillance 
in this animal species as well. Co-circulation of dif-
ferent influenza virus strains in swine may facilitate 
the generation of new variants that could potentially 
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pose a threat for public health [115]. For instance, it is 
assumed that influenza A(H1N1)pdm09 was present in 
swine herds for months before it emerged as a pan-
demic strain in humans [116]. Conversely, Nelson et al. 
[117] reported at least 49 transmission events of influ-
enza A(H1N1)pdm09 from humans to swine between 
2009 and 2011, as well as at least 23 separate intro-
ductions of human seasonal influenza into swine since 
1990. 
Although there is some evidence for infection in swine 
with non-H1 and non-H3 subtype viruses (H9N2, H4N6) 
[115,118], we found no case reports describing human 
infection with these influenza A virus subtypes after 
swine exposure. Since most human infection events 
are associated with swine exposure, awareness of risk 
factors and personal protective equipment is para-
mount to limiting the chance of infection and prevent-
ing people working with or recreationally exposed to 
swine (including children) from becoming ‘bridging 
links’ between swine and community contacts and vice 
versa [92,119].
There are a few limitations to this review. The language 
restriction set to papers published in English only and 
the unsystematic search of the grey literature probably 
lead to the omission of additional documented human 
infections with animal influenza virus. Although this 
limitation may affect the total count of human cases, 
the aim of this review was to identify animal influ-
enza subtypes, which crossed the species barrier to 
humans, and to our knowledge, all relevant subtypes 
were covered by this review.
Conclusions
There is evidence of infection of humans with animal 
influenza viruses belonging to various subtypes. All 
reported SIV cases have been exclusively associated 
with subtypes H1 and H3, and most AIV cases were 
caused by subtypes H5 and H7. Whether this reflects 
the prevalence of these viruses in birds kept or sold 
for consumption or a preferential ability to transmit to 
humans cannot be concluded from the available evi-
dence. Given the often, mild illness associated with 
non-H5 and non-H7 animal influenza virus infections 
in humans, such cases likely are underreported [120]. 
Standardisation of diagnostic methods has signifi-
cantly improved case ascertainment in recent years, 
but the monitoring of the evolution of these viruses 
is less advanced. Recent research pointed out that 
the majority of Asian and African countries have con-
tributed only few sequences to surveillance networks 
and do not regularly sequence viruses as part of their 
surveillance programme [121]. Genetic sequencing is 
paramount to identifying changes with potential effect 
on the phenotype of circulating influenza viruses, and 
could thereby strengthen worldwide epidemic and 
pandemic preparedness [121]. To be prepared for a 
potentially emerging influenza virus of animal origin in 
humans, enhanced global surveillance in animal popu-
lations is therefore indicated to monitor evolution and 
circulation of viruses with yet unknown public health 
risks.
Note: 
Numbers on influenza H5N1 and H7N9 are as of 31 January 
2014. 
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